Fighting Rejection: The Felzartamab Trial (Nephrology Transplant Journal Club - 5/21/2025)

Wednesday, May 21, 2025, 5:00 PM - 6:00 PM

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours), Participation Hours (1.00 hours)

Identify and discuss treatment expectations and updates on immunosuppressive regimens, pre-transplant management, and post-transplant comorbidities. Improve the overall clinical care and outcomes for nephrology transplant recipient candidates.

1. Evaluate the Safety and Tolerability of Felzartamab
2. Assess the Efficacy of CD38 Targeting in Reversing ABMR
3. Discuss the Therapeutic Potential and Limitations of Felzartamab in Transplant Rejection

The University of California, Davis, Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement:

The University of California, Davis, Health designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)^TM.   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accessibility Statement
 
University of California, Davis Health is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.

Mitigation of Relevant Financial Relationships

University of California, Davis Health Continuing Medical Education adheres to the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Date	Empty Column	Title
5/21/2025 5:00:00 PM	Fighting Rejection: The Felzartamab Trial (Nephrology Transplant Journal Club - 5/21/2025) 5/21/2025 5:00:00 PM 5/21/2025 6:00:00 PM 6 False MM/DD/YYYY	Fighting Rejection: The Felzartamab Trial (Nephrology Transplant Journal Club - 5/21/2025) Identify and discuss treatment expectations and updates on immunosuppressive regimens, pre-transplant management, and post-transplant comorbidities. Improve the overall clinical care and outcomes for nephrology transplant recipient candidates.

This activity is not commercially supported.